Time and Date: 12:30 p.m.–5:30 p.m., July 30, 1997.

Place: Teleconference originating at the NIOSH Grants Office, 1095 Willowdale Road, Morgantown, West Virginia 26505–2888.

Status: The meeting will be closed in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., and the Determination of the Associate Director for Management and Operations, CDC, pursuant to Pub. L. 92–463. Application(s) and/or proposal(s) and the discussions could reveal confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the application(s) and/or proposal(s), the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Purpose: The Task Group Session of the Safety and Occupational Health Study Section will review, discuss, and evaluate grant application(s) in response to the Institute's Request for Application Number 722, entitled ''Intervention Studies for Construction Safety and Health.''

It is the intent of NIOSH to support broad-based research endeavors which will lead to the prevention of work-related diseases and injuries in the construction industry by designing, implementing, and evaluating measures to reduce occupational hazards. If prevention measures are not currently available, new technologies should be developed for controlling hazardous exposures. Such new technologies must be evaluated to determine that the prevention measures are feasible, even for smaller businesses. Intervention research, of which control technology is a part, examines the utility and impact of new and existing preventive measures in the workplace. It is anticipated that research funded will promote these goals.

Agenda items are subject to change as priorities dictate.

Contact Person for More Information: Pervis C. Major, Ph.D., Scientific Review Administrator, Office of Extramural Coordination and Special Projects, Office of the Director, NIOSH, 1095 Willowdale Road, Morgantown, West Virginia 26505–2888, telephone 304/285–5979.

Dated: July 9, 1997.

Carolyn J. Russell,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 97–18501 Filed 7–14–97; 8:45 am]

BILLING CODE 4163–19–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Meeting

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the following committee meeting:

Name: Task Group Session of the Safety and Occupational Health Study Section, National Institute for Occupational Safety and Health (NIOSH).

Times and Dates: 8 a.m.–5:30 p.m., August 13, 1997. 8 a.m.–5:30 p.m., August 14, 1997.

Place: Hyatt Regency Washington on Capitol Hill, 400 New Jersey Avenue, Washington, DC, 20001.

Status: The meeting will be closed in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., and the Determination of the Associate Director for Management and Operations, CDC, pursuant to Pub. L. 92–463. Application(s) and/or proposal(s) and the discussions could reveal confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the application(s) and/or proposal(s), the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Purpose: The Task Group Session of the Safety and Occupational Health Study Section will review, discuss, and evaluate grant application(s) in response to the Institute's Request for Application Number 725, entitled ''Childhood Agricultural Safety and Health Research.''

It is the intent of NIOSH to support broad-based research endeavors which will maximize the safety and health of children and adolescents exposed to agricultural production hazards by expanding the knowledge base regarding etiology; outcomes; intervention strategies; and the effectiveness of commonly utilized educational materials and methods.

Research may address children directly involved in work tasks and/or other children exposed to agricultural production hazards. The funded research projects should cover a variety of types of agricultural production in different geographical regions (e.g. tomato harvesting in California, dairy farms in Wisconsin, and blueberry picking in Maine). It is anticipated that research funded will promote these goals.

Agenda items are subject to change as priorities dictate.

Contact Person for More Information: Pervis C. Major, Ph.D., Scientific Review Administrator, Office of Extramural Coordination and Special Projects, Office of the Director, NIOSH, 1095 Willowdale Road, Morgantown, West Virginia 26505–2888, telephone 304/285–5979.

Dated: July 9, 1997.

Carolyn J. Russell,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 97–18500 Filed 7–14–97; 8:45 am]

BILLING CODE 4163–19–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 97N–0260]

Agency Information Collection Activities: Proposed Collection; Comment Request

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing an opportunity for public comment on the proposed collection of certain information by the agency. Under the Paperwork Reduction Act of 1995 (the PRA), Federal agencies are required to publish notice in the **Federal Register** concerning each proposed collection of information and to allow 60 days for public comment in response to the notice. This notice solicits comments on voluntary customer/partner service surveys to implement Executive Order 12862.

DATES: Submit written comments on the collection of information by (*insert date 60 days after date of publication in the* **Federal Register**.)

ADDRESSES: Submit written comments on the collection of information to the Dockets Management Branch (HFA–305), Food and Drug Administration, 12420 Parklawn Dr., rm. 1–23, Rockville, MD 20857. All comments should be identified with the docket number found in brackets in the heading of this document.

FOR FURTHER INFORMATION CONTACT: Mark L. Pincus, Office of Information Resources Management (HFA–80), Food and Drug Administration, 5600 Fishers

Lane, rm. 16B–31, Rockville, MD 20857, 301–827–1471.

SUPPLEMENTARY INFORMATION: Under the PRA (44 U.S.C. 3501–3520), Federal agencies must obtain approval from the Office of Management and Budget (OMB) for each collection of information they conduct or sponsor. ''Collection of information'' is defined in 44 U.S.C. 3502(3) and 5 CFR 1320.3(c) and includes agency requests or requirements that members of the public submit reports, keep records, or provide information to a third party. Section 3506(c)(2)(A) of the PRA (44 U.S.C. 3506(c)(2)(A)) requires Federal agencies to provide a 60-day notice in the **Federal Register** concerning each proposed collection of information before submitting the collection to OMB for approval. To comply with this requirement, FDA is publishing notice of the proposed collection of information listed below.

With respect to the following collection of information, FDA invites comments on: (1) Whether the proposed collection of information is necessary for the proper performance of FDA's functions, including whether the information will have practical utility; (2) the accuracy of FDA's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques, when appropriate, and other forms of information technology.

Customer/Partner Service Surveys

Under section 903 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 393), FDA is authorized to conduct research relating to regulated articles and to conduct educational and public information programs relating to responsibilities of the agency. Executive Order 12862, entitled ''Setting Customer Service Standards,'' directs Federal agencies that ''provide significant services directly to the public'' to ''survey customers to determine the kind and quality of services they want and their level of satisfaction with existing services.'' FDA is seeking OMB clearance to conduct a series of surveys and focus groups to implement Executive Order 12862. Participation in the surveys and focus groups will be voluntary. This request covers customer service surveys of regulated entities, such as food processors; cosmetic, drug, biologic and medical device manufacturers; consumers; and health professionals. The request also covers partner surveys of State and local governments.

FDA will use the information gathered through surveys and focus groups to identify strengths and weaknesses in service to customers and partners and to make improvements. The surveys and focus groups will assess timeliness, appropriateness, accuracy of information, courtesy, and problem resolution in the context of individual programs.

FDA projects 12 customer service and 12 partner service surveys per year, with a sample of between 500 and 2,000 customers each. After the first year, some of these surveys will be repeats of earlier surveys, for purposes of monitoring customer/partner service and developing long-term data. Also, FDA plans to conduct 12 focus groups per year (6 for customers and 6 for partners), primarily for the purpose of gaining input into the design of service surveys.

FDA estimates the burden of this collection of information as follows:

ESTIMATED ANNUAL REPORTING BURDEN

Type of Survey	No. of Respondents	Annual Frequency per Response	Hours per Response	Total Hours
Mail/telephone surveys	36,000	1	.25	9,000
Focus Groups	120	1	1.5	180
Total	36,120	1	.255	9,180

There are no capital costs or operating and maintenance costs associated with this collection of information.

These estimates are based on experience with other surveys FDA has conducted.

Dated: July 7, 1997.

William K. Hubbard,

Associate Commissioner for Policy Coordination.

[FR Doc. 97–18525 Filed 7–14–97; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 97N–0226]

Elanco Animal Health; Withdrawal of Approval of NADA

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is withdrawing approval of a new animal drug application (NADA) held by Elanco Animal Health. The NADA provides for the use of tylosin soluble powder in animal drinking water. The sponsor requested the withdrawal of approval of the NADA because the animal drug product is no longer being marketed.

EFFECTIVE DATE: July 25, 1997.

FOR FURTHER INFORMATION CONTACT: Dianne T. McRae, Center for Veterinary Medicine (HFV–102), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301–594–1623.

SUPPLEMENTARY INFORMATION: Elanco Animal Health, A Division of Eli Lilly and Co., Lilly Corporate Center, Indianapolis, IN 46285, is the sponsor of NADA 13–029 Tylan® Plus Vitamins (tylosin), which provides for the use of tylosin in swine drinking water for control and treatment of swine dysentery. Elanco Animal Health requested withdrawal of approval of the NADA because the animal drug product is no longer being marketed.

Therefore, under authority delegated to the Commissioner of Food and Drugs (21 CFR 5.10) and redelegated to the Center for Veterinary Medicine (21 CFR 5.84), and in accordance with § 514.115 *Withdrawal of approval of applications* (21 CFR 514.115), notice is given that approval of NADA 13–029 and all supplements and amendments thereto is hereby withdrawn, effective July 25, 1997.